BPP 1001
Alternative Names: BPP-1001Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Bioscience Pharma Partners
- Class Anti-inflammatories
- Mechanism of Action 5-lipoxygenase-activating protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Neurological-disorders in USA (PO)
- 25 Jan 2023 Preclinical development in Neurological disorders is ongoing in USA (PO) (Bioscience Pharma Partners pipeline, January 2023)
- 25 Jan 2023 Bioscience Pharma Partners has patent protection for FLAP inhibitors in Australia, China, Denmark, Spain, Canada and other EU countries prior to January 2023